We measured the total or isoform specific gene expression of the JAZF1 (JAZF zinc finger 1), CTBP2 (C-terminal binding protein 2), LMTK2 (lemur tyrosine kinase 2), SLC22A3 (solute carrier family 22 extraneuronal monoamine transporter, member 3), MYEOV (myeloma overexpressed), MSMB (microseminoprotein beta) and HNF1B (HNF homeobox 1 beta) in a cohort of 39 non-malignant benign prostatic hyperplasia (BPH) samples and 21 prostate adenocarcinoma samples, and correlated gene expression with cancer status and with the genetic variants identified in the GWAS (table 1). This evidence concerns the gene LMTK2 and prostate adenocarcinoma.